Resources

PATH, in collaboration with the Maharashtra Department of Health and Family Welfare, conducted a biomedical equipment survey in health facilities across the state in January 2024. This report analyzes data collected through facility assessments to provide a snapshot of the medical oxygen ecosystem of 34 health facilities in 27 of Maharashtra’s 36 districts. The purpose of this work is to quantify existing oxygen delivery and production equipment, consumables for administering oxygen therapy, bed capacity, and facility infrastructure characteristics.

PATH, in collaboration with the Uttar Pradesh Department of Health and Family Welfare, conducted a biomedical equipment survey in health facilities across the state in January 2024. This report analyzes data collected through facility assessments to provide a snapshot of the medical oxygen ecosystem of 149 health facilities in 65 districts across Uttar Pradesh, India. The purpose of this work is to quantify existing oxygen delivery and production equipment, consumables for administering oxygen therapy, bed capacity, and facility infrastructure characteristics.

This slide provides a snapshot of the Group B Streptococcus (GBS) vaccine technology landscape, in the effort to track the development of GBS vaccine candidates and provide a summary of the various vaccine approaches being worked on around the world.This snapshot pairs with the GBS Vaccine Clinical Trial Tracker, which provides publicly available information on clinical trials of GBS vaccine candidates intended for disease prevention.To share any updates or corrections to the snapshot, please contact gbssnapshot@path.org.

This spreadsheet provides publicly available information on clinical trials of Group B Streptococcus (GBS) candidate vaccines intended for disease prevention.Sources of information for these trials include clinicaltrials.gov, who.int/clinical-trials-registry-platform, clinicaltrialsregister.eu, chictr.org.cn, and anzctr.org.au.Some information is also obtained through contact with investigators, sponsors, and funders of vaccine clinical trials. This spreadsheet pairs with the GBS Vaccine Snapshot, which provides a summary of the GBS vaccine candidates in development worldwide.To share any updates or corrections to the tracker, please contact gbssnapshot@path.org.

This report summarizes the proceedings from an international meeting organized by PATH and partners and held in Bangkok, Thailand, from September 3 to 4, 2025 for manufacturers and regulatory testing laboratories on polio vaccine quality control assays. Presenters provided updates on evolving guidance for the implementation of quality control assays for polio vaccines. This included the dissemination of results from a recent World Health Organization (WHO) collaborative study supporting the replacement of animal models with high-throughput sequencing for routine vaccine lot release. Other topics included the latest WHO collaborative study results on the suitability of the Sabin inactivated polio vaccine International Standard for in vivo rat potency testing; the availability of WHO universal reagents for polio vaccine potency assays; and the importance of harmonizing in-house assay standards and reagents with international standards and the WHO guidance. Finally, presenters discussed the potential of next-generation products, such as S19 virus-based IPV, that can be developed currently without biocontainment requirements.